Fig. 7

Adoptive transfer of Vγ2Vδ2 T cells expanded by pulse zoledronate stimulation with IL-15 in combination with pamidronate controlled PC-3 prostate tumor growth in NSG mice similarly to Vγ2Vδ2 T cells expanded by pulse zoledronate stimulation with IL-2. a Schema of treatment protocol used to evaluate the anti-tumor efficacy of Vγ2Vδ2 T cells. Immunodeficient NSG mice were s.c. inoculated with human PC-3 prostate cancer cells on day 0. On day 13, pamidronate (50 μg/kg) was given i.v. On day 14, 1 × 10⁶ purified Vγ2Vδ2 T cells expanded using pulse zoledronate stimulation with either IL-15 or IL-2 were inoculated i.v. Treatments were repeated weekly until week 6. Longitudinal and transverse diameters of the tumors were measured once weekly until week 9. b, left panel Vγ2Vδ2 T cells stimulated by pulse zoledronate exposure with IL-15 showed similar anti-tumor immunity compared with those expanded with IL-2. Mean PC-3 tumor volume ± SD is shown for 7–8 mice per group treated with either pamidronate alone (open triangles), pamidronate with purified Vγ2Vδ2 T cells derived by pulse zoledronate stimulation with IL-15 (open circles), or pamidronate with purified Vγ2Vδ2 T cells derived by pulse zoledronate stimulation with IL-2 (closed circles). ***p < 0.001 compared with mean tumor volume of mice treated with Vγ2Vδ2 T cells derived by pulse zoledronate stimulation with IL-2 using the Mann–Whitney U test. Right panel, Tumor volume at week 7 of individual mice treated with pamidronate alone (open triangles), pamidronate with Vγ2Vδ2 T cells derived by pulse zoledronate stimulation with IL-15 (open circles), or pamidronate with Vγ2Vδ2 T cells derived by pulse zoledronate stimulation with IL-2 (closed circles). Bars represent mean values. ***p < 0.001 using the Mann–Whitney U test